Mounjaro® KwikPen®

Your Mounjaro KwikPen price is determined by four factors: strength, number of pens, country of origin (Canada or the United Kingdom), and shipping. All prices are listed in US dollars (USD).

Because Mounjaro must remain cold, it ships cold-packed via Express shipping, added at checkout. Orders of fewer than 3 cold items from Canada incur a $50 surcharge, displayed before payment. You can avoid this surcharge by ordering 3 or more cold items or by choosing the United Kingdom option. Visit our shipping page for complete rates and details.

Before ordering, have your prescription, your doctor’s contact details, and a Visa or Mastercard ready.

1. Sign in or create a free account.

2. Select your prescribed strength, country of origin, and number of pens in the buy box, then add Mounjaro KwikPen to your cart.

3. Complete checkout and upload your prescription. You can also email it to service@canadianinsulin.com, or have your doctor email or fax it to 1-866-951-0118.

4. Receive a confirmation email once your order is placed; your medication ships cold-packed via Express shipping once processed.

Prefer to order by phone? Call 1-844-560-7790, or see how to order for all available options.

Each Mounjaro KwikPen is a multi-dose pen containing 4 fixed weekly doses at a single strength. Pen needles are not included. Listed strengths include:

Your prescriber determines your strength and when to adjust it. When your prescription changes, order the new strength exactly as written and expect your total to adjust accordingly.

Store unused Mounjaro KwikPens in the refrigerator between 2°C and 8°C (36°F and 46°F). Do not freeze them, and discard any pen that has been frozen. Keep pens in their original carton, away from direct heat and light.

Once in use, a pen may be kept at room temperature up to 30°C (86°F) for up to 30 days. Discard the pen after 4 weekly doses or 30 days after first use, whichever comes first, even if medication remains. When traveling, pack your pens in carry-on luggage rather than checked bags.

Mounjaro (tirzepatide) is a once-weekly injection targeting both GIP and GLP-1 receptors. Used alongside diet and exercise, it is approved to improve blood sugar control in adults with type 2 diabetes. It is not approved for type 1 diabetes and has not been studied in patients with a history of pancreatitis.

If you are seeking tirzepatide for chronic weight management, that indication belongs to Zepbound, a separate tirzepatide product. To learn more about type 2 diabetes, read our guides on the 3 P’s of diabetes, swollen feet and weeping legs in diabetes, and cellulitis and diabetes.

Mounjaro carries a boxed warning: in animal studies, tirzepatide caused thyroid C-cell tumors, though it is unknown whether it causes these tumors in humans. Do not use Mounjaro if you or a family member have had medullary thyroid carcinoma (MTC), if you have multiple endocrine neoplasia syndrome type 2 (MEN 2), or if you are allergic to tirzepatide. Contact your healthcare provider immediately if you notice a neck lump or swelling, trouble swallowing, hoarseness, or shortness of breath.

Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain. Serious side effects noted on the label include:

• Inflammation of the pancreas (pancreatitis)
• Low blood sugar when taken alongside insulin or a sulfonylurea
• Serious allergic reactions
• Kidney problems, which may result from dehydration caused by vomiting or diarrhea
• Severe stomach problems
• Vision changes in patients with diabetic retinopathy
• Gallbladder problems
• Food or liquid entering the lungs during surgery or procedures involving anesthesia

Mounjaro may reduce the effectiveness of oral birth control pills, so discuss alternative contraception with your healthcare provider. Seek immediate medical care for persistent severe stomach pain (with or without vomiting) or signs of an allergic reaction. This is not a complete list; consult the DailyMed tirzepatide label for full safety details.

Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors. The other medications we carry in this class target GLP-1 receptors only: Trulicity (dulaglutide) and Semaglutide (Generic Ozempic) are once-weekly pens, Victoza (liraglutide) is a once-daily pen, and Soliqua Solostar Pens combine a long-acting insulin with lixisenatide in a once-daily pen.

Each medication has distinct approved indications, strengths, and labeling, and they are not interchangeable. Your prescriber will determine which option suits your treatment plan. Browse all GLP-1 agonists.